Akebia Could Face Long, Costly Effort To Overcome Vadadustat CRL

Company Pins Hopes On Partner Otsuka’s EMA Application

 
• By Alaric DeArment
  
Akebia received a complete response letter for its CKD anemia drug, vadadustat • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip